Response to "helping melanoma patients decide whether to choose adjuvant high-dose interferon-alpha2b"

Oncologist. 2006 May;11(5):538-9; author reply 539-40. doi: 10.1634/theoncologist.11-5-538.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Chemotherapy, Adjuvant
  • Decision Making*
  • Humans
  • Interferon alpha-2
  • Interferon-alpha / administration & dosage*
  • Melanoma / drug therapy*
  • Recombinant Proteins

Substances

  • Antineoplastic Agents
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins